妇科恶性肿瘤术后性激素治疗及风险

Hormone therapy and its risk after gynecological malignancy operation

随着治疗水平提升,妇科恶性肿瘤患者生存期不断延长,因而改善妇科恶性肿瘤生存者的生存质量成为医生们面临的新挑战。妇科恶性肿瘤患者可能自身正处于围绝经期,也可能是由于肿瘤治疗导致人工绝经,其更年期症状可能较正常年龄自然绝经女性更明显。对于妇科恶性肿瘤术后患者是否可以给予性激素治疗,目前仍有一定争议。临床医生需针对不同的原发病,在患者知情同意的基础上,审慎个体化用药。

With the improvement of therapy,the survival time of patients with gynecological malignant tumor is prolonged,so improving their quality of life has become a new challenge for doctors.These patients may be in perimenopause themselves,or be in artificial menopause due to tumor treatment,and their climacteric symptoms are more obvious than those in natural menopause.Whether hormone therapy could be used to relieve the climacteric symptoms in these patients is still controversial at present.Clinicians should give individualized hormone therapy cautiously on the basis of patients’ informed consent.